ARTICLE | Company News
FDA accepts Idec's BLA filing
January 2, 2001 8:00 AM UTC
The FDA accepted for filing the BLA for IDPH's Zevalin radiolabeled antibody to treat low grade or follicular, relapsed or refractory, CD20-positive, B cell non-Hodgkin's lymphoma (NHL), and follicula...